Results 21 to 30 of about 5,144 (141)
Background: Monocyte to high-density lipoprotein cholesterol ratio (MHR) is a novel inflammatory biomarker which has been associated with cardiovascular diseases. Objective: To study MHR in patients with psoriasis treated with biological agents. Methods:
Funda Tamer +2 more
doaj +1 more source
The role of ixekizumab in non-radiographic axial spondyloarthritis
Among patients with axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA) is distinguished from ankylosing spondylitis (AS) by a lack of obvious radiographic changes in the sacroiliac joint. Tumor necrosis factor inhibitor (
Bon San Koo, Tae-Hwan Kim
doaj +1 more source
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco +8 more
wiley +1 more source
Updated COVID‐19 Vaccines and Health Outcomes in Patients With Autoimmune Rheumatic Conditions
Objective We aimed to assess the association between COVID‐19 vaccination status and COVID‐19‐related hospital admissions, need for mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and death in people with autoimmune rheumatic conditions. Methods We conducted a retrospective cohort study using National Clinical Cohort Collaborative
Lesley E. Jackson +127 more
wiley +1 more source
Objective To assess the association between duration of targeted therapy exposure and cancer risk in patients with spondyloarthritis (SpA), including those with psoriatic arthritis, axial SpA, and other subtypes. Methods This nationwide cohort study used the French health insurance database to identify adults with SpA initiating a targeted therapy ...
Karine Tankovic +7 more
wiley +1 more source
Introduction Real-world data on ixekizumab utilization in axial spondyloarthritis (axSpA) are limited. We evaluated ixekizumab treatment patterns and health care resource utilization (HCRU) in patients with axSpA using United States Merative L.P ...
Abhijeet Danve +6 more
doaj +1 more source
Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz +2 more
wiley +1 more source
Successful subcutaneous desensitization in a patient with systemic reaction due to ixekizumab
Background: Ixekizumab is a high-affinity IgG4 monoclonal humanized antibody useful for the treatment of ankylosing spondylitis. Benign skin reactions are a common adverse event with ixekizumab but systemic hypersensitivity reactions are much more ...
Diego Gutiérrez Fernández +7 more
doaj +1 more source
Psoriatic transversal nail grooves on biologics
We noticed transverse grooves on the nails of a psoriasis vulgaris patient being treated with ixekizumab. The indentation might have appeared during the period when the effective concentration of ixekizumab was low and psoriasis activity in the nail ...
Keiichi Yamanaka, Makoto Kondo
doaj +1 more source
In this prospective observational cohort study, 34 patients with moderate‐to‐severe psoriasis received biologic therapy (anti‐TNF‐α, anti‐IL‐12/23, or anti‐IL‐17) for 6 months. Carotid intima–media thickness decreased significantly in the overall cohort (p < 0.01), with the greatest reductions in the anti‐IL‐17 and anti‐IL‐12/23 groups.
Harika Ödemiş +6 more
wiley +1 more source

